hotspot -WSS

hotspot

author：entertainment 2025-09-02 08:19:50 - browse：765

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： At Orexo, a ‘turning point’ for everything but digital health

entertainment

WSS

Abortion clinic in Cancun will cater to Americans

10 million people disenrolled from Medicaid over past six months

WHO calls for emergency meeting on new China virus, as cases spread

How dance can help nurses traumatized by Covid

AI can’t replace a physician’s gut feeling

Study: New antibiotic targets gonorrhea as well as last existing drug

leisure time

hotspot

explore

Bright Health sells Medicare Advantage business to Molina

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

The high cost of giving birth even with insurance

Medicare has a new plan to address drug shortages

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Cancer drug shortages should be causing more outrage

WHO calls for emergency meeting on new China virus, as cases spread

explore

Custom gene therapy hints at new path for rare disease treatments

Victims of gun violence feel impacts long after bullet wound

Startup Neumora takes a novel depression drug to Phase 3

Medicare will require more price transparency from hospitals

Group opposing PBM reform sets lobbying record

HPV cancer vaccine study demonstrates efficacy

leisure time

leisure time

entertainment

entertainment